The identified guidelines were generally evidence-based, though there was some use of secondary evidence reviews, including other guidelines, rather than original literature reviews and evidence synthesis. In type 1 diabetes guidelines, the option of different insulin regimens (mostly meal-time ? basal or premix regimens) was recommended depending on patient need. Type 2 diabetes guidelines either recommended a glycosylated hemoglobin target of \7.0% (\53 mmol/mol) (70% of guidelines) or \6.5% (\47 mmol/mol) (30% of guidelines) as the ideal glycemic target. Most guidelines recommended a target fasting plasma glucose that fell within the range of 
INTRODUCTION
The worldwide prevalence of diabetes was estimated as 366 millions in 2011 (8.3% of the population), and is predicted to rise to 552 millions (9.9%) by 2030 [1] . The total number of excess deaths due to diabetes in 2011 in the 20-79 age group was estimated to be nearly 4.6 million (6.8% of global deaths) [2] . According to forecasts, diabetes will have an increasing impact on years of life lost due to premature death and disability, shifting from the eleventh to seventh most common cause of death by 2030 [3] . In addition, diabetes has an important economic burden; globally, 12% of health expenditure was expected to be spent on diabetes in 2010 [4] . The greatest increases in diabetes prevalence have occurred in countries in economic transition, in particular in the Middle East, sub-Saharan Africa, China, and the Indian subcontinent [5] . This has the potential to put severe strain on healthcare systems in these countries [6] [7] [8] .
There are a number of internationally recognized guidelines, algorithms, and position statements for the diagnosis, control, and management of diabetes [9-13], covering a range of different components of diabetes care, often with an emphasis on glucose-lowering therapies. These factors together with updates make use and implementation of the latest versions of the guidelines desirable but challenging [14] [15] [16] [17] [18] . However, implementation of guidelines for the management of diabetes has beneficial effects for the individual with diabetes, including a significant reduction in complications associated with diabetes, such as hospitalizations [19] .
Despite the increasing burden of disease, measures of the use of guidelines repeatedly show poor implementation of, and adherence to, current recommendations [20, 21] . The quality of disease management is reduced because there is a gap between guideline recommendations and clinical practice [21] .
Amongst reasons for non-implementation of guidelines may include poor access to the guidelines for clinicians, and the reduced access to healthcare resources of the target population [22] .
Development and implementation of local standards of care quality to ensure 'local ownership' are considered important in securing a basis for guideline implementation [23] . Indeed, implementation of diabetes clinical practice guidelines have resulted in increases in the percentage of patients reaching glycosylated hemoglobin (HbA 1c ) and low-density lipoprotein (LDL) targets [23, 24] .
Compliance with national standards of care has been shown to make a substantial difference in the control of chronic diseases, such as diabetes [21, 25] .
The purpose of the current study was to identify the establishment of national guidelines for the management of diabetes for a range of countries where income is changing from a low base, to investigate the coverage of these local guidelines, and to discuss the differences between different local guidelines and between local and international guidelines.
METHODS

Search Strategy and Terms
Searches were conducted using Medline, Guidelines that were not in English were translated using Google translate, including translations from Spanish, Portuguese, French, Indonesian, Hebrew, and Thai. Some guidelines could not be translated using the Google translate program and in these instances the guidelines were translated and tabulated by a local clinical advisor who was a native speaker, kindly provided by the local Novo Nordisk affiliate.
Analysis
The following parameters were assessed in the national guidelines: the source of the guidelines, e.g., whether from a national society or from the ministry of health; year of most recent guideline; year of previous guidelines; whether national guidelines were specifically based on international guidelines or consensus documents; whether specific recommendations for pediatric populations, the elderly, and gestational diabetes were present; post-prandial control; management of hypoglycemia;
recommended first-, second-, and third-line insulin treatment for type 1 diabetes (if any);
and recommended first-, second-, and third-line therapies for type 2 diabetes (if any). This article does not contain any studies with human beings or other animals performed by any of the authors. Nine of the 25 (36%) country guidelines specified a second-line insulin regimen.
Intensification with a meal-time ? basal regimen was specified by four countries, use of insulin pump therapy was specified by two countries, and three countries suggested more than one option for intensification. Two countries mentioned a third-line management option of intensification of meal-time ? basal insulin therapy.
Targets for Glycemic Control
Targets for glycemic control varied between guidelines. However, all guidelines either recommended an HbA 1c target of \7.0%
(\53 mmol/mol) (70% of guidelines) or \6.5%
(\47 mmol/mol) (30% of guidelines) as the ideal glycemic target (Table 3) Twelve of 32 (38%) guidelines suggested that insulin therapy could be considered second-line in conjunction with metformin or another oral agent. The type of insulin was unspecified in 42% of guidelines, but in 42% basal insulin as a single insulin was an option, and in 25% premixed insulin was an option.
Third-line therapy was specifically mentioned in 30 guidelines, with an additional oral agent suggested as an option in 40% of these. Insulin therapy was suggested as an option by 25 of 30 (83%) guidelines. Of these guidelines, the type of insulin was not specified in 44% of guidelines (e.g., insulin initiated according to the patients' needs), beginning with basal insulin was recommended in 44%, with premixed insulin in 32%, long-acting in 12%, and 20% of guidelines allowed initiation with more than one specified insulin regimen (e.g., initiate with long-acting or long-acting plus rapid-acting or premixed).
Guidelines from 22 of 33 (67%) countries made specific provision for post-prandial blood glucose control within their diabetes guidelines. A problem with international guidelines is that they can give so many alternative treatment options that the less specialist practitioner may fail to make the optimum treatment recommendations for each type of patient. In addition, complex regimens may lead to payors agreeing to reimburse the cheapest available option(s). National guidelines that allow multiple treatment options but discuss the benefits and weaknesses of individual classes of glucose-lowering therapies may then be closer to assisting health-care professionals in meeting the medical needs of people with type 2 diabetes.
Another consideration is whether provision is made in national guidelines for specific clinical situations, post-prandial blood glucose control, and hypoglycemia. Guidelines from 67% of countries in the study made some provision for PPG control, with use of a rapid-acting insulin as part of a meal-time ? basal insulin regimen the most common recommendation, and an alpha-glucosidase inhibitor was recommended in some guidelines. Guidelines from 70% of countries made provision for hypoglycemia.
A limitation of the current study is that it has not been comprehensive in the inclusion of all available national guidelines for all the countries, but has specifically focussed on treatment guidelines, which may have introduced bias into the final analysis. A further limitation was that some national guidelines may have been inadvertently missed because they were not freely available on the internet or were restricted to a non-English website. Some countries may also have one or more national guidelines that they refer to. Furthermore, the study had to rely on translation of guidelines from the original language into English for many countries, and this may have led to the inclusion of inaccuracy or inconsistencies in the analysis. For guidelines that could not be translated using
Google translation, the accuracy of the data depended on the interpretation of a local clinical advisor provided by Novo Nordisk who translated the guidelines from the native language. Also, the study did not include guidelines for special groups, such as recommendations for the management of diabetes during Ramadan [30] [31] [32] . However, the authors note that guidelines on the management of diabetes during Ramadan stress the importance of individualizing treatment to meet the patient's needs [30] [31] [32] .
CONCLUSION
In conclusion, national guidelines were identified for 33 out of 75 (44%) lower income countries, of which 76% also had guidelines for type 1 diabetes. Two-thirds of countries with national guidelines for type 2 diabetes had made the latest version of their guidelines available after 2008, enabling the latest treatment options to be included. Given that, the consensus algorithms developed by ADA/ EASD have been criticized because they were based mostly on expert opinion rather than on an evidence-based process [26, 30] . Therefore, it is notable that many national guidelines seem now to have adopted a more evidence-based approach. Furthermore, with regular updating to reflect the rapid pace of change in the management of type 2 diabetes, this suggests that quality national guidelines may benefit a wider international population of people with diabetes.
However, establishment of national guidelines is only the first step in achieving a high quality of disease management and more efforts need to be made for clinicians and patients to adhere to the recommendations of national guidelines, since glycemic control is still poor in the countries where this study was conducted. 
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